SCHEMBL16420536

SCHEMBL16420536

COCCNCc1ccc(-c2nnc(-c3cncc(-c4ccc(SC(C)C)cc4)n3)o2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 6/20 0.56
L3MBTL1 Q9Y468 1/20 0.39
BRAF P15056 1/20 0.35
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
PRKD1 Q15139 1/20 0.35
TBK1 Q9UHD2 1/20 0.33
AKT1 P31749 1/20 0.32
SYK P43405 1/20 0.32
PIM1 P11309 1/20 0.32
PIM3 Q86V86 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 2/20 0.31
GAA P10253 2/20 0.31
HPGD P15428 2/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
P4HTM Q9NXG6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16420564 0.89 ATR (0.58) ATRSMN1; SMN2
SCHEMBL17826152 0.87 ATR (0.56) ATRPIM1PIM3PIM2KDM4E
SCHEMBL16420587 0.87 ATR (0.73) ATRBRAFTLR8TLR7TBK1
SCHEMBL16424870 0.85 ATR (0.79) ATR
SCHEMBL20278567 0.83 ATR (0.46) ATRSYK
SCHEMBL16420684 0.82 ATR (0.43) ATRSYKPIM1PIM3PIM2
SCHEMBL16489021 0.76 ATR (0.57) ATRL3MBTL1BRAFPRKD1TBK1
SCHEMBL16424903 0.73 ATR (0.81) ATR
SCHEMBL16424850 0.72 ATR (1.00) ATR
SCHEMBL18177419 0.72 ATR (0.47) ATRSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365557-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-14 US disclosed
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031661-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 ATR 1/4885L3MBTL1 3422/4885BRAF 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.